Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of DM199 in Healthy Volunteers
NCT02868996Phase 1Completed
- Sponsor
- DiaMedica Therapeutics
- Start
- Sep 2016
- Primary completion
- Mar 2017
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of rinvecalinase alfa in acute ischemic stroke (AIS) (6 arms), sponsored by DiaMedica Therapeutics. Primary endpoint: Number of participants with treatment-related adverse events at 30 days. Started Sep 2016; status: completed.
02
Drugs
rinvecalinase alfa
03
Conditions
acute ischemic stroke (AIS)
Beyond the preview
Go deeper on NCT02868996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02868996.